Loading
A phase 1/2 trial of Trastuzumab rezetecan, Carboplatin, Bevacizumab in ovarian cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer is a phase 1/2 interventional study registered as NCT06840002 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 150 participants planned, started 2025-03-18 and due to reach its primary completion in 2026-12. Interventions recorded: SHR-A1811, Carboplatin, Bevacizumab, Oxaliplatin for Injection, Paclitaxel injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab rezetecan, CAPOX (capecitabine, oxaliplatin), Jiangsu Hengrui Pharmaceuticals, Bevacizumab.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads).